Abstract:COVID-19 is the name of the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that occurred in 2019. The virus-host-specific interactions, molecular targets on host cell deaths, and the involved signaling are crucial issues, which become potential targets for treatment. Spike protein, angiotensin-converting enzyme 2 (ACE2), cathepsin L-cysteine peptidase, transmembrane protease serine 2 (TMPRSS2), nonstructural protein 1 (Nsp1), open reading frame 7a (ORF7a), viral main protease (3C-like protease (3CLpro) or Mpro), RNA dependent RNA polymerase (RdRp) (Nsp12), non-structural protein 13 (Nsp13) helicase, and papain-like proteinase (PLpro) are molecules associated with SARS-CoV infection and propagation. SARS-CoV-2 can induce host cell death via five kinds of regulated cell death, i.e., apoptosis, necroptosis, pyroptosis, autophagy, and PANoptosis. The mechanisms of these cell deaths are well established and can be disrupted by synthetic small molecules or natural products. There are a variety of compounds proven to play roles in the cell death inhibition, such as pan-caspase inhibitor (z-VAD-fmk) for apoptosis, necrostatin-1 for necroptosis, MCC950, a potent and specific inhibitor of the NLRP3 inflammasome in pyroptosis, and chloroquine/hydroxychloroquine, which can mitigate the corresponding cell death pathways. However, NF-κB signaling is another critical anti-apoptotic or survival route mediated by SARS-CoV-2. Such signaling promotes viral survival, proliferation, and inflammation by inducing the expression of apoptosis inhibitors such as Bcl-2 and XIAP, as well as cytokines, e.g., TNF. As a result, tiny natural compounds functioning as proteasome inhibitors such as celastrol and curcumin can be used to modify NF-κB signaling, providing a responsible method for treating SARS-CoV-2-infected patients. The natural constituents that aid in inhibiting viral infection, progression, and amplification of coronaviruses are also emphasized, which are in the groups of alkaloids, flavonoids, terpenoids, diarylheptanoids, and anthraquinones. Natural constituents derived from medicinal herbs have anti-inflammatory and antiviral properties, as well as inhibitory effects, on the viral life cycle, including viral entry, replication, assembly, and release of COVID-19 virions. The phytochemicals contain a high potential for COVID-19 treatment. As a result, SARS-CoV-2-infected cell death processes and signaling might be of high efficacy for therapeutic targeting effects and yielding encouraging outcomes.

Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy

Repurposing of Kinase Inhibitors for Treatment of COVID-19

Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication

Computational View Toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.

Host protein kinases required for SARS-CoV-2 nucleocapsid phosphorylation and viral replication

Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections

Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.

Recent clinical findings on the role of kinase inhibitors in COVID-19 management

The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology

Targeting cytokine storm as the potential anti-viral therapy: Implications in regulating SARS-CoV-2 pathogenicity

PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy

Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking

Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets

Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development

PAK1-blockers: Potential Therapeutics Against COVID-19

Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication

Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy

Protease-activated receptor 1 as a potential therapeutic target for COVID-19

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)